Abstract: The present invention relates to a bone implant with a porous lithium tantalate membrane and a method for preparing the bone implant. The bone implant comprises: (1) a substrate; and (2) a porous membrane on the substrate, wherein the substrate is selected from the group consisting of a tantalum substrate, a niobium substrate, a tantalum-niobium alloy substrate and a titanium substrate, and wherein the porous membrane is selected from the group consisting of a porous lithium tantalate membrane, a porous lithium niobate membrane, a porous lithium tantalate-lithium niobate mixture membrane and a porous titanium oxide membrane.

Abstract: The present invention relates to a method for manufacturing a colored product, in particular a colored mobile phone shell, comprising the following steps: (1) providing a product substrate, preferably a shell substrate; and (2) surface-treating the product substrate, preferably shell substrate, by an anodic oxidation method and/or a molten salt electrochemical method, wherein the product substrate, preferably shell substrate, is made of materials selected from the group consisting of tantalum, niobium, a tantalum-niobium alloy, titanium and a titanium alloy.

Abstract: An engineered microbial cell expressing a ?-amyrin synthase, a cytochrome P450 reductase, a cytochrome P450 C28 oxidase, a cytochrome P450 C16 oxidase and a cytochrome C23 oxidase is used to make quillaic acid from ?-amyrin.

Abstract: The present invention provides for a cyclopropane compound having the following chemical formula: wherein ? is —H or —COOR, wherein R is —H or an alkyl group, such as —CH3, —CH2CH3, —(CH2)2—CH3, —(CH2)3—CH3, or —C(CH3)3; ? is each independently wherein at least one ? is and, n is an integer from 3 to 11. A fuel composition comprising the cyclopropane compound thereof and a fuel additive. The present invention also provides for a system or genetically modified host cell capable of producing the cyclopropane compound, and a method for producing the cyclopropane compound.

Abstract: The disclosure provides for covalent organic frameworks (COFs) that constructed from weaving a plurality of long organic threads together. In particular, the disclosure provides for the construction of woven COFS, where long organic strands are connected together in a woven pattern using organic ligands/complexes that when orientated in certain geometries are capable of reversibly binding metal ions.

Abstract: The disclosure provides for covalent organic frameworks (COFs) that constructed from weaving a plurality of long organic threads together. In particular, the disclosure provides for the construction of woven COFS, where long organic strands are connected together in a woven pattern using organic ligands/complexes that when orientated in certain geometries are capable of reversibly binding metal ions.

Abstract: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Abstract: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Abstract: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Abstract: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Abstract: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Abstract: Methods of using imidazo[1,2-?]pyridine ether compounds for modulating ion channel activity in a warm-blooded animal are disclosed.

Abstract: Novel compounds and pharmaceutical compositions containing such compounds and possessing anti-tussive activity, and a method of administering the same to warm-blooded animals, including humans.

Abstract: Novel compounds and pharmaceutical compositions containing such compounds and possessing anti-tussive activity, and a method of administering the same to warm-blooded animals, including humans.

Abstract: Novel compounds and pharmaceutical compositions containing such compounds and possessing anti-tussive activity, and a method of administering the same to warm-blooded animals, including humans.

Abstract: Imidazo[1,2-&agr;]pyridine ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment or prevention of atrial or ventricular arrhythmia as well as atrial or ventricular fibrillation.

Abstract: Novel compounds and pharmaceutical compositions containing such compounds and possessing anti-tussive activity, and a method of administering the same to warm-blooded animals, including humans.

Abstract: Compounds and pharmaceutical compositions containing such compounds and possessing anti-tussive activity, and a method of administering the same to warm-blooded animals, including humans.